Immuron Limited
IMRN
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinalā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.82
Price-4.65%
-$0.04
1Y
Price
Market Cap
$4.668m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in AUD.-86.6%
EBITDA Margin-84.0%
Net Profit Margin-65.1%
Free Cash Flow Margin-86.6%
EBITDA Margin-84.0%
Net Profit Margin-65.1%
Free Cash Flow MarginRevenue
$7.287m
+122.9%
1y CAGR+143.5%
3y CAGR+213.8%
5y CAGREarnings
-$5.216m
-13.3%
1y CAGR-43.1%
3y CAGR-15.8%
5y CAGREPS
-$0.90
-10.7%
1y CAGR-42.5%
3y CAGR-15.1%
5y CAGRBook Value
$8.032m
$10.093m
Assets$2.061m
Liabilities$117.130k
DebtDebt to Assets
1.2%
-
Debt to EBITDAFree Cash Flow
-$6.137m
-56.5%
1y CAGR-57.2%
3y CAGR-43.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company